AstraZeneca (NASDAQ:AZN) Releases Earnings Results, Misses Estimates By $0.05 EPS

AstraZeneca (NASDAQ:AZN) issued its quarterly earnings results on Thursday. The company reported $1.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05), Zacks reports. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%.

AstraZeneca Stock Up 3.4 %

Shares of AZN traded up $2.44 during midday trading on Thursday, hitting $73.38. The company had a trading volume of 5,428,889 shares, compared to its average volume of 4,970,766. The company’s 50-day simple moving average is $67.27 and its 200-day simple moving average is $73.70. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $87.68. The firm has a market capitalization of $227.56 billion, a P/E ratio of 35.12, a P/E/G ratio of 1.18 and a beta of 0.46.

Analyst Ratings Changes

A number of analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.